Key Highlights
- ALNY shares are trading up 8.17% to $266.22.
- The rally follows strongly positive data presented at the ESC Congress reinforcing vutrisiran's clinical profile across ATTR-CM patient populations.
- A HELIOS-B subgroup analysis showed consistent all-cause mortality and cardiovascular event benefits regardless of baseline tafamidis use.
- The move sharply outperforms the broader healthcare sector amid a market backdrop pressured by rising bond yields and oil prices.
- Shares had fallen roughly 40% year to date after the company cut 2026 Amvuttra Revenue guidance by $200 million in late July, though Piper Sandler maintains an Overweight rating and a $489 price target.
Cardiology Data at ESC Congress Drives the Rally
Alnylam Pharmaceuticals (NASDAQ:ALNY) shares are surging as investors digest strongly positive data presented at the European Society of Cardiology Congress, reinforcing the clinical profile of vutrisiran, marketed as Amvuttra, across patients with transthyretin amyloid cardiomyopathy. Alnylam is a Cambridge, Massachusetts-based biopharmaceutical company and pioneer in RNA interference therapeutics, a Nobel Prize-winning technology that silences disease-causing genes.
A subgroup analysis from the company's HELIOS-B trial showed consistent all-cause mortality and cardiovascular event benefits regardless of whether patients were also taking tafamidis, a competing therapy, at baseline, a result that reinforces vutrisiran's positioning even in patients already on standard-of-care treatment.
Rally Sharply Outperforms a Pressured Healthcare Sector
The stock's advance is sharply outperforming the broader healthcare sector, which remains under pressure from rising bond yields and oil prices tied to escalating U.S.-Iran tensions. Alnylam also announced upcoming presentations at the Wells Fargo and Morgan Stanley healthcare conferences this month, keeping investor attention on the company as a leader in RNAi-based medicine.
Recovery From a Volatile, Guidance-Cut Stretch
Today's move follows a volatile stretch for the stock, which had fallen roughly 40% year to date after Alnylam cut its 2026 Amvuttra revenue guidance by $200 million in late July. Piper Sandler has maintained an Overweight rating and a $489 price target throughout the pullback, viewing the decline as overdone given the drug's underlying growth trajectory.
Amvuttra's Cardiology Data Reopens the Growth Narrative
Alnylam shares are rebounding as today's cardiology data offers fresh support for the growth thesis behind Amvuttra, even after a guidance cut had weighed heavily on sentiment earlier this summer. Continued clinical evidence supporting broader ATTR-CM adoption, alongside commentary at this month's healthcare conferences, will likely be the next catalysts investors watch.




_11_17_2026_20_37_58_946960.jpg)

Please wait processing your request...